{"meshTags":["Proto-Oncogene Proteins B-raf","Antineoplastic Combined Chemotherapy Protocols","Retrospective Studies","Drug Administration Schedule","Male","Time Factors","Aged","Kaplan-Meier Estimate","Skin Neoplasms","Aged, 80 and over","Mutation","Adult","Oximes","Molecular Targeted Therapy","Female","Humans","Indoles","Protein Kinase Inhibitors","Antibodies, Monoclonal","Sulfonamides","Melanoma","Italy","Treatment Outcome","Disease Progression","Middle Aged","Imidazoles","Young Adult"],"meshMinor":["Proto-Oncogene Proteins B-raf","Antineoplastic Combined Chemotherapy Protocols","Retrospective Studies","Drug Administration Schedule","Male","Time Factors","Aged","Kaplan-Meier Estimate","Skin Neoplasms","Aged, 80 and over","Mutation","Adult","Oximes","Molecular Targeted Therapy","Female","Humans","Indoles","Protein Kinase Inhibitors","Antibodies, Monoclonal","Sulfonamides","Melanoma","Italy","Treatment Outcome","Disease Progression","Middle Aged","Imidazoles","Young Adult"],"genes":["BRAF","BRAF","BRAF","BRAF"],"publicationTypes":["Journal Article","Multicenter Study","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Of 93 patients with pretreated, BRAF(V600) mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n \u003d 45) or after (n \u003d 48) treatment with ipilimumab 3 mg/kg, median overall survival (mOS) from first treatment was 9.9 and 14.5 months, respectively. Among patients treated with a BRAF inhibitor first, mOS from the end of BRAF inhibition was 1.2 months for those who did not complete ipilimumab treatment as per protocol, compared with 12.7 months for those who did (p \u003c .001). Prospective, randomized studies are required to determine the optimal sequencing of ipilimumab and BRAF inhibitors in patients with BRAF-mutated metastatic melanoma.","title":"Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.","pubmedId":"24484235"}